Date: 2015-11-30
Type of information: Nomination
Compound:
Company: Acadia Pharmaceuticals (USA - CA)
Therapeutic area: CNS diseases - Neurological diseases - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 30, 2015, Acadia Pharmaceuticals announced the appointment of Srdjan (Serge) Stankovic as Executive Vice President, Head of Research and Development. With a background in clinical and academic psychiatry, Dr. Stankovic brings over 20 years of executive level experience in drug development and clinical and medical affairs. Dr. Stankovic has built and led multidisciplinary teams for small molecules and biologics in therapeutic areas including neurology, psychiatry, oncology, cardiology and pain. He has led teams to achieve approvals of Keppra®, Fentora®, Treanda®, Nuvigil® and Aristada™. Dr. Stankovic most recently served as Senior Vice President of Clinical Development and Medical Affairs at Alkermes plc. from 2013 to 2015. Prior to Alkermes, he held the position of Senior Vice President and Head of Global Clinical Development for Teva Pharmaceuticals Ltd. He was appointed to this role following Teva’s acquisition of Cephalon, Inc. where he served as Senior Vice President, Worldwide Clinical Research. Dr. Stankovic also held executive positions in research and development at Forest Laboratories, Inc., Neurogen Corporation, Johnson and Johnson, and UCB. Dr. Stankovic received his M.D. from the University of Belgrade and holds a Master of Science in Public Health from the University of Alabama at Birmingham.
Financial terms:
Latest news:
